featured
Results of a Study of an LHRH Agonist ± Abiraterone Acetate + Prednisone for High-Risk Prostate Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
European Urology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Clinical and Biological Characterisation of Localised High-Risk Prostate Cancer: Results of a Randomised Preoperative Study of a Luteinising Hormone-Releasing Hormone Agonist With or Without Abiraterone Acetate Plus Prednisone
Eur Urol 2019 Oct 01;76(4)418-424, E Efstathiou, JW Davis, L Pisters, W Li, S Wen, RP McMullin, M Gormley, D Ricci, M Titus, A Hoang, AJ Zurita, N Tran, W Peng, T Kheoh, A Molina, P Troncoso, CJ LogothetisFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Advanced Prostate Cancer Center of Excellence
Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.